A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT03398005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03398005
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03398005. Randomized; double masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2019-07-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
Acronym
TRILOGY 1
Condition
Hypertriglyceridemia
Intervention (Drug)
CaPre
Intervention (Drug)
Placebo
Lead sponsor
Grace Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct03398005
Content hash
c60aaf0c6f67081270396250d70cb29e0a6e015a0ef5f6dfbbba929f25520bf1